[Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
MAO B selective inhibitor was given to parkinsonism patients for several months. Positive effect was found in half of the patients irrespective of their age, time of the disease onset and its severity. The drug proved most effective in bradykinesia. Its use is most expedient in combination with L-DOPA-containing drugs which prolong the effect and reduced diurnal shifts in the patients' conditions. Side effects are seldom observed and usually weak.
Stoliarova
L G
LG
Kadykov
A S
AS
Shvedkov
V V
VV
Shakhparonova
N V
NV
D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline
Opyt primeneniia selektivnykh ingibitorov monoaminoksidazy pri lechenii bol'nykh parkinsonizmom.